Mainz Biomed N.V. (MYNZ) Financials

Mainz Biomed N.V. (MYNZ) reported diluted earnings per share of -$2.70 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Mainz Biomed N.V. (MYNZ) had EBITDA of -$15.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

Mainz Biomed N.V. (MYNZ) had a gross margin of 72.6% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

Mainz Biomed N.V. (MYNZ) has a return on equity of -2526.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

Mainz Biomed N.V. (MYNZ) recorded an outflow of $11.0M in free cash flow during fiscal year 2025. This represents a 37.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

Mainz Biomed N.V. (MYNZ) recorded an outflow of $11.0M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

Mainz Biomed N.V. (MYNZ) had $5.3M in total assets as of fiscal year 2025, including both current and long-term assets.

Mainz Biomed N.V. (MYNZ) invested $1K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

Mainz Biomed N.V. (MYNZ) invested $4.9M in research and development during fiscal year 2025.

Mainz Biomed N.V. (MYNZ) had 10M shares outstanding as of fiscal year 2025.

Mainz Biomed N.V. (MYNZ) had a current ratio of 0.90 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

Mainz Biomed N.V. (MYNZ) had a debt-to-equity ratio of 7.30 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

Mainz Biomed N.V. (MYNZ) had a return on assets of -304.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

At the end of fiscal year 2025, Mainz Biomed N.V. (MYNZ) held $889K in cash, cash equivalents and investments, and reported an operating cash outflow of $11.0M over that year. Dividing the one by the other, the reported balance equals about 1 month of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

Mainz Biomed N.V. (MYNZ) has an Altman Z-Score of -36.22, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

Mainz Biomed N.V. (MYNZ) has a Piotroski F-Score of 3 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Mainz Biomed N.V. (MYNZ) reported a net loss of $16.2M while operations used $11.0M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Mainz Biomed N.V. (MYNZ) reported an operating loss of $16.1M against $373K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.